Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? [Yahoo! Finance]
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade) [Seeking Alpha]
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia [Yahoo! Finance]
Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch [Seeking Alpha]